StockNews.com Upgrades BioLineRx (NASDAQ:BLRX) to “Sell”

BioLineRx (NASDAQ:BLRX) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research note issued to investors on Friday.

Separately, HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of BioLineRx in a research note on Tuesday, March 26th.

BioLineRx Trading Up 2.4 %

Shares of BioLineRx stock opened at $0.72 on Friday. The company’s fifty day simple moving average is $1.11 and its 200-day simple moving average is $1.37. The stock has a market capitalization of $51.92 million, a PE ratio of -0.80 and a beta of 1.38. BioLineRx has a 1-year low of $0.65 and a 1-year high of $2.53. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.53 and a quick ratio of 1.47.

BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings results on Thursday, March 28th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.07. The business had revenue of $4.80 million for the quarter, compared to analysts’ expectations of $0.17 million. During the same quarter in the prior year, the business earned ($0.09) EPS. As a group, equities analysts anticipate that BioLineRx will post -1.03 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Rathbones Group PLC purchased a new position in shares of BioLineRx during the 3rd quarter valued at $72,000. B. Riley Wealth Advisors Inc. lifted its stake in shares of BioLineRx by 88.5% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 21,300 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 10,000 shares in the last quarter. Allen Mooney & Barnes Investment Advisors LLC purchased a new position in shares of BioLineRx during the 3rd quarter valued at $46,000. Values First Advisors Inc. purchased a new position in shares of BioLineRx during the 3rd quarter valued at $88,000. Finally, Geneos Wealth Management Inc. increased its holdings in BioLineRx by 72.3% in the 3rd quarter. Geneos Wealth Management Inc. now owns 40,500 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 17,000 shares during the last quarter. Hedge funds and other institutional investors own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.